Compare AbCellera Biologics Inc (ABCL) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Ryanair Holdings plc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Ryanair Holdings plc trades at $65.74 (market cap $32.49B). The key difference: Ryanair Holdings plc is far larger — about 13.8× AbCellera Biologics Inc's market cap, and Ryanair Holdings plc pays a 1.49% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | RYAAY | |
|---|---|---|
Market Cap | $2.35B | $32.49B |
Sector | Health | Industrials |
52-Week High | $8.12 | $73.82 |
52-Week Low | $2.78 | $53.24 |
Enterprise Value | $1.99B | $30.15B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Ryanair Holdings (RYAAY) trades at $66.35, up 1.31% with bullish technical signals from moving averages. The company demonstrates strong fundamentals with a P/E of 14.42, net income margin of 13.98%, and consistent earnings beats. Recent traffic growth of 7% in June 2026 and improved family seating policy reflect operational strength. Cash flow from operations remains robust at $3.42B despite negative net cash flow of -$12M in 2025.
RYAAY presents a compelling investment case with analyst consensus favoring Buy (62.5%) and bullish technical indicators. The airline's debt-free balance sheet, 80% fuel hedge for 2027, and cost leadership provide competitive advantages. Key risks include rising operating costs, macroeconomic uncertainty, and potential regulatory pressures. The stock's current valuation appears reasonable given strong profitability metrics and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
